Posted by: Market Watch in Market Information 23 minutes in the past Novavax mentioned it’s starting a Section 2b medical trial in South Afr
Novavax mentioned it’s starting a Section 2b medical trial in South Africa to guage the efficacy of NVX-CoV2373, its COVID-19 vaccine candidate. The Invoice & Melinda Gates Basis offering $15 million grant towards trial, mentioned Novavax, which final week agreed to promote its vaccine to the U.Okay. authorities if profitable. “As a result of South Africa is experiencing a winter surge of COVID-19 illness, this essential Section 2b medical trial has the potential to supply an early indication of efficacy, together with further security and immunogenicity information for NVX-CoV2373,” mentioned Gregory Glenn, president of analysis and improvement at Novavax. Market Pulse Tales are Speedy-fire, quick information bursts on shares and markets as they transfer. Go to MarketWatch.com for extra data on this information.
Learn Full Story
